Skip to main content
Formula Atlas
Regulation & Standards

FDA Exempt Infant Formula 21 CFR 107.30 — The Hypoallergenic Registration Pathway

FDA's 21 CFR 107.30 creates a separate registration pathway for infant formulas intended for diagnosed medical conditions — the legal basis for Nutramigen, Similac Alimentum, EleCare, Neocate, and other hypoallergenic and amino acid formulas. Distinct from the standard 21 CFR 107 framework governing healthy term infant formulas.

By María López Botín· Last reviewed · 5 min read
FDA Exempt Infant Formula 21 CFR 107.30 — The Hypoallergenic Registration Pathway
On this page
  1. Why the exempt category exists
  2. What 21 CFR 107.30 actually requires
  3. What's classified under 21 CFR 107.30
  4. The clinical implications for families
  5. What this means for parents reading labels
  6. Frequently asked questions
  7. Related reading
By María López Botín · Mother of 2, researching infant formula and infant nutrition since 2018

This site provides research and comparisons, not medical advice. Consult your pediatrician before changing your baby's formula.

The FDA's regulatory framework for infant formula has two distinct pathways. The standard pathway governed by 21 CFR 107 covers formulas intended for healthy term infants — Similac, Enfamil, Bobbie, Earth's Best, and most retail-shelf formulas live here. The exempt pathway under 21 CFR 107.30 governs formulas intended for diagnosed medical conditions — extensively hydrolyzed (Nutramigen, Similac Alimentum, Gerber Extensive HA), amino acid (EleCare, Neocate, Puramino), some metabolic-disease formulas, and certain premature-infant formulas.

21 CFR 107.30 is the FDA registration pathway for infant formulas that don't meet standard 21 CFR 107 nutritional adequacy because they are intended for infants with specific medical conditions (CMPA, inborn metabolic errors, prematurity). Manufacturers must notify FDA ≥90 days before marketing, document the medical indication, and demonstrate clinical adequacy. The exempt pathway is what makes hypoallergenic and amino acid formulas legally distinct from standard formulas — and why insurance coverage often requires documented diagnosis matching the registered indication.

Why the exempt category exists

Per FDA 21 CFR Part 107 Subpart B, standard 21 CFR 107 mandates specific nutrient ranges (protein, fat, carbohydrate, vitamins, minerals) appropriate for healthy term infants. A formula meeting all those ranges is "nutritionally adequate" by FDA definition.

Some clinical situations require formulas that deliberately fall outside those ranges. Cow milk protein allergy (CMPA) requires extensively hydrolyzed protein peptides under 3,000 daltons — which changes the protein profile in ways that don't match standard 21 CFR 107 spec. Phenylketonuria (PKU) requires phenylalanine- restricted protein — also outside spec. Premature infants need elevated calorie density and adjusted protein-to-energy ratios.

Without the exempt pathway, these clinically necessary formulas would technically be "nutritionally inadequate" per FDA standards and couldn't be marketed. The exempt pathway permits them under documented medical indication.

What 21 CFR 107.30 actually requires

The exempt pathway is not a free pass — it has its own structured requirements:. This section walks through the practical specifics so families and pediatricians can apply the framework to a particular feeding scenario without ambiguity.

1. Pre-market notification. Manufacturers must notify the FDA at least 90 days before marketing an exempt formula. The notification includes the medical indication, the formula's specific composition, clinical evidence supporting the formulation choices, and labeling language.

2. Documented medical indication. The exempt formula must be "intended for use in the dietary management of a specific disease or condition." Generic "for sensitive babies" is not a sufficient indication; CMPA, galactosemia, premature infants, or specific metabolic disorders are.

3. Clinical adequacy demonstration. The manufacturer must provide evidence the formula supports normal growth and development in the target population. Clinical trials, case series, or documented use in pediatric medicine all qualify depending on the indication.

4. Labeling distinct from standard formula. Exempt formulas must clearly state the medical indication on the label and include "Use under medical supervision" language. This is why every can of Nutramigen, EleCare, Neocate, etc. carries a clinical indication notice — it's a regulatory requirement, not a marketing choice.

5. Periodic recertification. Manufacturers must re-notify FDA when reformulating, when the indication changes, or when clinical evidence base updates significantly.

What's classified under 21 CFR 107.30

Per the FDA guidance on exempt formulas, the exempt category includes:. The specifics below follow the site's primary-source methodology and reflect the editorial judgement applied across every comparable record in the Atlas.

Hypoallergenic formulas (FDA-recognized). Extensively hydrolyzed formulas (eHF) for diagnosed CMPA: Nutramigen with Enflora LGG, Similac Alimentum (powder + ready-to-feed), Gerber Extensive HA.

Amino acid formulas (AAF). Maximum-hypoallergenic for eHF non- responders: EleCare Infant, Neocate Syneo Infant, Puramino Infant. These are also used for eosinophilic esophagitis and multi-allergy cases.

Metabolic disease formulas. PKU formulas, MSUD formulas, galactosemia-restricted formulas, and similar inborn-error-of- metabolism products. Mostly prescribed by metabolic specialists.

Premature infant formulas. NeoSure (Abbott), EnfaCare (Mead Johnson), and similar elevated-calorie products for premature infants past hospital discharge.

Soy-protein formulas for galactosemia. ProSobee and Isomil are exempt-pathway products primarily for galactosemia, not for general "sensitive baby" use.

The clinical implications for families

Insurance coverage typically requires diagnosis matching the registered indication. Most US insurers (Aetna, BCBS, United, Cigna) reimburse exempt formulas with documented diagnosis. The diagnosis must match the formula's registered indication — Nutramigen for CMPA is reimbursable; Nutramigen "for fussy baby" is not.

WIC coverage varies by state. Some states cover exempt formulas in WIC for diagnosed CMPA with appropriate documentation; others require parents to navigate insurance separately. State WIC offices are the authority.

FSA/HSA accounts always cover exempt formulas with appropriate documentation, regardless of insurance reimbursement status. Federal regulations recognize them as qualified medical expenses.

"Hypoallergenic" without exempt registration is NOT the same. Partially hydrolyzed formulas (HiPP HA, NAN HA, Enfamil Gentlease) are NOT registered under 21 CFR 107.30 — they're standard 21 CFR 107 formulas with marketing positioning. The protein peptides in pHF are too large to qualify as FDA-recognized hypoallergenic. This is why pHF doesn't treat diagnosed CMPA.

What this means for parents reading labels

When you see "Hypoallergenic" prominently on a formula label, look for these signals to know whether it's truly exempt-registered:

  • Statement of medical indication on the front of the label ("for the dietary management of cow milk protein allergy")
  • "Use under medical supervision" language
  • Higher price tier (~$3-5/oz prepared)
  • Distribution through pharmacies, medical supply, or insurance/WIC channels — not standard retail shelf
  • Prescription typically required by insurance for reimbursement

If the formula has none of these signals, it's not exempt-registered. "HA," "comfort," "sensitive," and "gentle" branding does NOT automatically mean exempt registration. Read the indication carefully.

Frequently asked questions

What's the difference between FDA-registered and FDA-exempt infant formula?
FDA-registered formulas under 21 CFR 107 meet standard nutritional adequacy ranges for healthy term infants — Similac, Enfamil, Bobbie, Earth's Best, etc. FDA-exempt formulas under 21 CFR 107.30 are intended for specific medical conditions and intentionally fall outside those ranges. Both are FDA-supervised; they have different registration pathways and different intended populations. Exempt formulas require documented medical indication, ≥90-day pre-market notification, clinical adequacy evidence, and labeling stating the indication.
Why is Nutramigen classified as exempt but Enfamil Gentlease is standard?
Nutramigen is extensively hydrolyzed (peptides under 3,000 daltons) — the protein profile doesn't meet standard 21 CFR 107 protein adequacy ranges, so it requires exempt 21 CFR 107.30 registration with CMPA as the medical indication. Enfamil Gentlease is partially hydrolyzed (peptides 5,000-10,000 daltons) — the protein profile does meet standard 21 CFR 107 ranges, so it registers as a standard formula despite carrying 'gentle' and 'HA' marketing positioning. The peptide size determines the regulatory pathway, not the marketing language.
Does insurance always cover exempt formulas for CMPA?
Usually yes with documented diagnosis, but coverage varies. Most major insurers (Aetna, BCBS, United, Cigna) reimburse exempt formulas (Nutramigen, Alimentum, EleCare, Neocate, Puramino) when the prescribing pediatrician or allergist documents CMPA via elimination-and-challenge, IgE-specific testing, or symptom-resolution-on-elimination. Coverage typically reimburses 60-100%; exact percentages depend on the plan. Pre-authorization is sometimes required. Without diagnosis documentation, exempt formulas are not insurance-reimbursable — the diagnosis-to-indication match is the gating criterion.
Can I buy exempt formula without a prescription?
Yes. Exempt formulas are over-the-counter — no prescription required to purchase. The FDA registration pathway requires manufacturers to label them 'use under medical supervision' but doesn't restrict retail sale. The prescription requirement comes from insurance carriers (for reimbursement) and from pediatric medical practice (for ongoing supervision), not from FDA. You can buy Nutramigen, Alimentum, or EleCare directly from a pharmacy or online retailer without a prescription.
How long does it take FDA to clear an exempt formula notification?
Per 21 CFR 107.30, manufacturers must notify FDA at least 90 days before marketing. FDA reviews the notification, can request additional information, and can object within the 90-day window if the formula doesn't meet exempt-pathway requirements. In practice, the actual clearance timeline depends on whether FDA requests additional clinical data or reformulation. Established manufacturers (Reckitt, Abbott, Nestlé, Nutricia) with extensive prior submissions typically clear in 90-120 days; new entrants can take longer if FDA requests more clinical evidence.
Do European hypoallergenic formulas (HiPP HA, Aptamil HA) follow 21 CFR 107.30?
No. European hypoallergenic formulas are governed by EU Regulation 2016/127 + Commission Regulation (EU) 2016/128 (the medical-foods regulation), which has its own classification framework distinct from FDA's 21 CFR 107.30. EU classifications include 'foods for special medical purposes' (FSMP) which roughly parallel the US exempt category but have different specific requirements. When a European exempt formula reaches families via personal-use enforcement discretion, it isn't FDA-registered under 21 CFR 107.30 — it's imported under the broader enforcement-discretion framework. This is one reason why HiPP HA isn't a CMPA treatment in the US clinical sense; the regulatory recognition is different.
What happens if a manufacturer ships an unregistered exempt formula?
FDA can issue a warning letter, a recall demand, or seek injunctive relief depending on severity. The Abbott Sturgis facility shutdown in 2022 was driven partly by the manufacturer's regulatory failure plus Cronobacter contamination concerns — including for exempt formulas (EleCare, Similac Alimentum) produced at that facility. Exempt formulas are subject to FDA's full inspection authority because they're medical foods used in vulnerable populations; regulatory non-compliance has more severe consequences than for standard formulas.